Y10T 436/105831
Protein or peptide standard or control [e.g., hemoglobin, etc.]
Y10T436/105831 (Protein or peptide standard or control [e.g., hemoglobin, etc.]) appears on 368 US grants and 287 published applications in this corpus.
Search patents in Y10T- Granted patents
- 368
- Published applications
- 287
- Assignees
- 232
- Inventors
- 625
- Latest grant
- 24 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 7 | 0 |
| 1978 | 4 | 0 |
| 1979 | 2 | 0 |
| 1980 | 4 | 0 |
| 1981 | 6 | 0 |
| 1982 | 1 | 0 |
| 1983 | 2 | 0 |
| 1984 | 8 | 0 |
| 1985 | 4 | 0 |
| 1986 | 3 | 0 |
| 1987 | 7 | 0 |
| 1988 | 2 | 0 |
| 1989 | 6 | 0 |
| 1990 | 1 | 0 |
| 1991 | 5 | 0 |
| 1992 | 4 | 0 |
| 1993 | 2 | 0 |
| 1994 | 5 | 0 |
| 1995 | 11 | 0 |
| 1996 | 11 | 0 |
| 1997 | 8 | 0 |
| 1998 | 15 | 0 |
| 1999 | 8 | 0 |
| 2000 | 5 | 0 |
| 2001 | 19 | 9 |
| 2002 | 11 | 19 |
| 2003 | 9 | 31 |
| 2004 | 24 | 19 |
| 2005 | 21 | 28 |
| 2006 | 15 | 15 |
| 2007 | 15 | 17 |
| 2008 | 9 | 9 |
| 2009 | 15 | 24 |
| 2010 | 15 | 16 |
| 2011 | 15 | 52 |
| 2012 | 20 | 15 |
| 2013 | 16 | 11 |
| 2014 | 9 | 7 |
| 2015 | 7 | 7 |
| 2016 | 2 | 0 |
| 2017 | 2 | 3 |
| 2018 | 5 | 2 |
| 2019 | 1 | 1 |
| 2020 | 1 | 0 |
| 2021 | 1 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for determining genetic polymorphisms in the TMEM216 gene24 Feb 2026US 12,559,798 B2The Regents of the University of California
- Mass spectrometric quantitation13 Apr 2021US 10,976,321 B2Electrophoretics Limited
- Compositions and methods for determining genetic polymorphisms in the TMEM216 gene8 Sep 2020US 10,767,227 B2The Regents of the University of California
- Sharply resolving labeled protein molecular weight standards28 May 2019US 10,302,591 B2Life Technologies Corporation
- Diaspirin crosslinked pegylated hemoglobin24 Jul 2018US 10,029,001 B2
- Compositions and methods for determining genetic polymorphisms in the tmem216 gene24 Sep 2026US 2026/0286437 A1The Regents of the University of California
- Compositions and methods for determining genetic polymorphisms in the tmem216 gene28 Jan 2021US 2021/0025004 A1The Regents of the University of California
- Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-111 Jul 2019US 2019/0212330 A1
- Compositions and methods for determining genetic polymorphisms in the tmem216 gene12 Jul 2018US 2018/0195126 A1The Regents of the University of California
- Sharply resolving labeled protein molecular weight standards1 Feb 2018US 2018/0031522 A1Life Technologies Corporation
Most cited
By later US patents
- Therapy and diagnosis of conditions related to telomere length and/or telomerase activity143US 5,489,508 AUniversity of Texas System Board of Regents · 1996
- Redox reversible bipyridyl-osmium complex conjugates126US 7,045,310 B2Roche Diagnostics Operations, Inc. · 2006
- Novel polymerized, cross-linked, stromal-free hemoglobin120US 4,001,200 AAlza Corporation · 1977
- Lysable blood preservative composition116US 4,040,785 ATechnicon Instruments Corporation · 1977
- Particulate solid phase immobilized protein quantitation116US 6,696,304 B1Luminex Corporation · 2004